ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 23rd Annual Investment Conference
September 13, 2021 07:30 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences appoints accomplished biotechnology executive, Josh Mandel-Brehm, to its Board of Directors
September 01, 2021 07:30 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences Closes Upsized US$20,125,000 Public Offering
August 25, 2021 09:44 ET
|
ProMIS Neurosciences Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO and CAMBRIDGE, Mass., Aug. 25, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (the...
ProMIS Neurosciences Inc. Announces Upsize of Previously Announced Public Offering of Units to US$17.5M
August 18, 2021 10:49 ET
|
ProMIS Neurosciences Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 18, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX: PMN), a...
ProMIS Neurosciences Inc. Announces Pricing of US$15 Million Public Offering of Units
August 18, 2021 07:10 ET
|
ProMIS Neurosciences Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 18, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX: PMN), a...
ProMIS Neurosciences Inc. Announces US$15 Million Offering of Units
August 17, 2021 16:40 ET
|
ProMIS Neurosciences Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX: PMN), a...
ProMIS Neurosciences Announces Second Quarter 2021 Results
August 12, 2021 07:30 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and...
ProMIS Neurosciences Issues Chairman’s Memorandum
August 04, 2021 07:30 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences to Present at 2021 Alzheimer’s Association International Conference
July 22, 2021 07:15 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences Obtains Receipt for Final Base Shelf Prospectus
July 08, 2021 07:30 ET
|
ProMIS Neurosciences Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO and...